Literature DB >> 24710471

Pharmacologic management of perioperative pulmonary hypertension.

Julie W Cheng1, Adriano R Tonelli, Gosta Pettersson, Richard A Krasuski.   

Abstract

Perioperative pulmonary hypertension can originate from an established disease or acutely develop within the surgical setting. Patients with increased pulmonary vascular resistance are consequently at greater risk for complications. Despite the various specific therapies available, the ideal therapeutic approach in this patient population is not currently clear. This article describes the basic principles of perioperative pulmonary hypertension and reviews the different classes of agents used to promote pulmonary vasodilation in the surgical setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710471      PMCID: PMC3982201          DOI: 10.1097/FJC.0000000000000050

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  80 in total

Review 1.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension.

Authors:  Harm J Bogaard; Kohtaro Abe; Anton Vonk Noordegraaf; Norbert F Voelkel
Journal:  Chest       Date:  2009-03       Impact factor: 9.410

2.  Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.

Authors:  Gaetano Palma; Raffaele Giordano; Veronica Russolillo; Sabato Cioffi; Sergio Palumbo; Marco Mucerino; Vincenzo Poli; Carlo Vosa
Journal:  Tex Heart Inst J       Date:  2011

3.  Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension.

Authors:  Banashree Mandal; Poonam Malhotra Kapoor; Ujjwal Chowdhury; Usha Kiran; Minati Choudhury
Journal:  Ann Card Anaesth       Date:  2010 May-Aug

4.  A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Authors:  Robyn J Barst; D Dunbar Ivy; Guillermo Gaitan; Andras Szatmari; Andrzej Rudzinski; Alberto E Garcia; B K S Sastry; Tomas Pulido; Gary R Layton; Marjana Serdarevic-Pehar; David L Wessel
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

5.  Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery.

Authors:  Tsvetomir Loukanov; Dietrich Bucsenez; Wolfgang Springer; Christian Sebening; Helmut Rauch; Eva Roesch; Matthias Karck; Matthias Gorenflo
Journal:  Clin Res Cardiol       Date:  2011-02-13       Impact factor: 5.460

6.  Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery.

Authors:  Juliano L Fernandes; Roney O Sampaio; Carlos M Brandão; Tarso Augusto D Accorsi; Luiz F Cardoso; Guilherme S Spina; Flavio Tarasoutchi; Pablo Pomerantzeff; Jose O Auler; Max Grinberg
Journal:  Am J Cardiol       Date:  2011-02-04       Impact factor: 2.778

7.  Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.

Authors:  Lynette M Brown; Hubert Chen; Scott Halpern; Darren Taichman; Michael D McGoon; Harrison W Farber; Adaani E Frost; Theodore G Liou; Michelle Turner; Kathy Feldkircher; Dave P Miller; C Gregory Elliott
Journal:  Chest       Date:  2011-03-10       Impact factor: 9.410

8.  Pulmonary vascular resistance in infants after cardiac surgery: role of carbon dioxide and hydrogen ion.

Authors:  A C Chang; H A Zucker; P R Hickey; D L Wessel
Journal:  Crit Care Med       Date:  1995-03       Impact factor: 7.598

9.  A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.

Authors:  Tanveer A Khan; Gabriel Schnickel; David Ross; Sam Bastani; Hillel Laks; Fardad Esmailian; Daniel Marelli; Ramin Beygui; Richard Shemin; Larry Watson; Irina Vartapetian; Abbas Ardehali
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 5.209

10.  Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease.

Authors:  Alisa Limsuwan; Suthep Wanitkul; Anant Khosithset; Sukasom Attanavanich; Piya Samankatiwat
Journal:  Int J Cardiol       Date:  2007-12-21       Impact factor: 4.164

View more
  1 in total

1.  Beyond the evidence: treating pulmonary hypertension in the intensive care unit.

Authors:  Seth R Bauer; Adriano R Tonelli
Journal:  Crit Care       Date:  2014-10-16       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.